Pharmaceutical CAS 206361-99-1 Darunavir Purity Darunavir Material Darunavir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Darunavir
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Darunavir
• Name: Darunavir Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 206361-99-1
• Mf: C27h37n3o7s
• MW: 547.66358
• Melting Point: 74-76°c
• Density: 1.34
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical CAS 206361-99-1 Darunavir Purity Darunavir Material Darunavir

Product Description

Product Details

Product name	Darunavir
Appearance	White powder
CAS NO.	206361-99-1
MF	C27H37N3O7S
MW	547.66358

Darunavir is the latest weapon in the arsenal of agents to combat human immunodeficiency virus type 1(HIV-1).
As an HIV-1 protease inhibitor, its mechanism of action involves blocking the cleavage of the gag and gag-pol polyproteins into functional proteins essential for the production of infectious progeny virus;

the result is the production of immature, noninfectious viral particles.

Compared to predecessor HIV protease inhibitors, darunavir retains activity against resistant stains, a critical factor with the continual emergence of multidrug- resistant (MDR) mutants. Despite experiencing a 13-fold reduction in binding to MDR HIV-1 protease, this binding is 1.5 orders of magnitude tighter than the first-generation protease inhibitors.

Application&Function

Darunavir exhibits less than a 10-fold decrease in susceptibility in cell culture against 90% of 3309 clinical isolatesresistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir.In contrast, darunavir-resistant viruses display limited susceptibility to only tipranavir, suggesting limited cross-resistance between these two protease inhibitors.To avoid the issues of the peptide-based protease inhibitors, darunavir has evolved from a structure-based design effort to minimize peptidic features and reduce molecular weight and complexity.

Specification